CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Darifenacin hydrobromide

Last Updated: October 1, 2008
Result type: Reports
Project Number: S0147
Product Line: Reimbursement Review

Generic Name: Darifenacin hydrobromide

Brand Name: Enablex

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Bladder, overactive

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: April 16, 2009

Recommendation Type: List with clinical criteria and/or conditions